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ABSTRACT: 
The sirtuins, silent mating-type information regulation 2 (SIRTs), are a family of nicotinamide adenine 
dinucleotide (NAD+)-dependent histone deacetylases with important roles in regulating energy 
metabolism and senescence. Activation of SIRTs appears to have beneficial effects on lipid metabolism 
and antioxidants, prompting investigation of the roles of these proteins in atherogenesis. Although clinical 
data are currently limited, the availability and safety of SIRT activators such as metformin and resveratrol 
provide an excellent opportunity to conduct research to better understand the role of SIRTs in human 
atherosclerosis. Encouraging observations from preclinical studies necessitate rigorous large, prospective, 
randomized clinical trials to determine the roles of SIRT activators on the progression of atherosclerosis 
and ultimately on cardiac outcomes, such as myocardial infarction and mortality. 
 
Keywords: Atherosclerosis, CVD, Sirtuin, SIRT1, SIRT3, SIRT6, Oxidative Stress, Lipid metabolism. 
 
Abbreviations: ABC, Adenosine triphosphate binding cassette; ABCG, ABC sub-family G member; ADP, 
Adenosine diphosphate; AMPK, Adenosine monophosphate-activated protein kinase; eNOS, Endothelial 
nitric oxide synthase; FOXO, Forkhead transcription factor subclass O; HDL-C , High-density lipoprotein 
cholesterol; HIF1A, Hypoxia-inducible factor 1A; HUVEC, Human umbilical vein endothelial cells; 
LDL-C, Low-density lipoprotein cholesterol; LDLR, Low-density lipoprotein receptor; LOX-1, Lectin-
like oxidized low-density lipoprotein receptor-1; LXR, Liver X receptor; MnSOD, Manganese-dependent 
superoxide dismutase; NAD, Nicotinamide adenine dinucleotide; NADPH, Nicotinamide adenine 
dinucleotide phosphate (reduced form) ; N-CoR, Nuclear receptor co-repressor; NF-κB, Nuclear factor 
κB; NFATc2, Nuclear factor of activated T cells 2; ox-LDL,Oxidized low-density lipoprotein; p53, Tumor 
protein 53; PCSK9, Proprotein convertase subtilisin/kexin 9; PGC-1α, Peroxisome proliferator-activated 
receptor-γ co-activator-1α; ROS, Reactive oxygen species; SIRT, Silent mating-type information 
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regulation; SOD2, Superoxide dismutase 2; SR-B1, Scavenger receptor class B type I; STAT3, Signal 
transducer and activator of transcription-3; VCAM-1, Vascular cell adhesion molecule-1, 
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1. Sirtuins family 
The sirtuins, silent mating-type information regulation 2 (SIRTs), are a family of nicotinamide adenine 
dinucleotide (NAD+)-dependent histone deacetylases. SIRTs are activated in response to low cellular 
energy stores and have been implicated in the control of many physiological processes including 
senescence (1). The life-prolonging effects of SIRTs were first described in Saccharomyces cerevisiae (2). 
The regulation of SIRTs by NAD+ dictates that the activity of these enzymes alters in response to changes 
in prevailing intracellular redox potential (1) and SIRTs have been found to have important roles in energy 
regulation (3). The main chemical reactions catalyzed by sirtuin enzymes are protein lysine 
deacetylations. Sirtuins couple the deacetylation of lysine to the hydrolysis of NAD+ by transferring the 
acetyl group to the adenosine diphosphate (ADP)-ribose moiety to form O-acetyl-ADP-ribose, releasing 
free nicotinamide (4). Seven closely-related SIRT family members have been identified and these are 
divided into four classes: class I (consisting of SIRT1, SIRT2, and SIRT3), class II (SIRT4), class III 
(SIRT5), and class IV (SIRT6 and SIRT7) (5, 6). The SIRTs have a conserved core catalytic domain, but 
they differ with respect to their distribution in tissues and their intracellular locations (7). SIRT1, SIRT6 
and SIRT7 are predominantly located in the nucleus, SIRT2 is unique in its cytoplasmic location, and 
SIRT3, SIRT4 and SIRT5 are mitochondrial SIRTs (8). Of the seven SIRT subtypes, SIRT1, SIRT3, and 
SIRT6 have been most extensively characterized and are the focus of this narrative review. 
 
1.1.1. SIRT1 
SIRT1 is a highly conserved NAD-dependent histone deacetylase (6) and is the best characterized member 
of the SIRT family. SIRT1 is highly expressed in human vascular endothelial cells (9), where it resides in 
the nucleus of the cell and is associated with euchromatin (10). SIRT1 regulates many cellular processes 
essential for cell survival, apoptosis, inflammation, stress resistance, cell growth, cell senescence and 
metabolism, by deacetylating histones and many non-histone proteins such as forkhead transcription 
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factors (FOXOs), nuclear factor κB (NF-κB), tumor protein 53 (p53), peroxisome proliferator-activated 
receptor-γ co-activator-1α (PGC-1α), and several DNA damage repair proteins including Ku70 (11-14). 
SIRT1 deficiency contributes to increased inflammation, oxidative stress, foam cell formation, impaired 
nitric oxide (NO) production and autophagy, thereby promoting vascular aging and atherosclerosis (11-
14).  
 
1.1.2. SIRT3 
SIRT3 regulates several mitochondrial functions and it has important roles in maintaining homeostasis, 
particularly under conditions of stress (15). However, SIRT3 does not appear to be a prerequisite for life, 
as demonstrated by knockout mice models which showed an almost normal phenotype at birth - although 
these animals displayed excessive acetylation of mitochondrial proteins (16). SIRT3 participates in the 
control of fatty-acid metabolism, and SIRT3 knockout mice demonstrate abnormal lipid metabolism 
which is associated with abnormal accumulation of acylcarnitines and triglycerides in the livers of these 
animals during fasting (17). Multiple cellular targets including manganese-dependent superoxide 
dismutase (MnSOD), NADH dehydrogenase sub-complex 9, and succinate dehydrogenase complex 
subunit A have been identified as being modulated by SIRT3 (18, 19). SIRT3 provides protection against 
oxidative stress by deacetylation and activation of superoxide dismutase 2 (20). Roos et al.  indicated that 
loss of SIRT3 does not change endothelial function in advanced atherosclerosis, but may lead to 
augmentation of osteogenic signaling and accelerated progression of vascular calcification (21). 
 
1.1.3. SIRT6 
The core domain of SIRT6 is flanked by a N-terminal which is necessary for histone deacetylation and 
chromatin association and a C-terminal which is required for the nuclear localization of this SIRT subtype 
(22). Primarily characterized as an NAD+-dependent histone deacetylase (23), SIRT6 targets the histones 
H3K9 (10) and H3K56 (24) and also directly deacetylases a variety of proteins (24, 25). SIRT6 expression 
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is decreased in atherosclerotic lesions from ApoE−/− mice (26) and human patients (27). However, the 
role of SIRT6 in regulating vascular endothelial function and atherosclerosis is not well understood. 
Recently Xu et al.  reported that SIRT6 reduces the formation of atherosclerotic lesions via the attenuation 
of endothelial dysfunction and vascular inflammation (28) . 
 
1.1.4. Putative therapeutic roles of SIRTs 
SIRTs regulate a variety of genes which encode proteins that regulate inflammation and endothelial cell 
function (10). The importance of SIRTs in many physiological processes has led to pathophysiological 
and therapeutic roles being investigated in a variety of conditions including cancer, diabetes mellitus, and 
cardiovascular disease (1), all leading causes of morbidity and mortality (29). Cardiac (3, 30, 31) and 
cardiovascular (1, 32) effects of SIRTs have been extensively reviewed elsewhere. SIRT1 has been 
implicated in protection against endothelial dysfunction, thrombosis, myocardial infarction and 
reperfusion injury. SIRT3 appears to have beneficial effects on the myocardium, ameliorating 
cardiomyopathy and left ventricular hypertrophy by preserving mitochondrial function (33). SIRT6 has 
similar effects and additionally may have beneficial effects on lipid profiles. Hepatic Sirt6 might suppress 
transcription of Pcsk9, which prevent hepatic low-density lipoprotein receptor (LDLR) degradation and 
subsequently reduce plasma LDL cholesterol (LDL-C) levels in mice (34). 
 
2. Atherosclerosis 
Atherosclerosis is a progressive disorder, which develops from foam cells and fatty streaks in arterial 
walls through several stages of development, ultimately resulting in atherosclerotic plaques. The plaques 
can obstruct blood flow. In the coronary circulation this can result in symptoms of angina pectoris. If the 
plaques rupture, they expose the platelets to pro-aggregatory stimuli leading to thrombogenesis and its 
sequelae: coronary thrombosis and myocardial infarction. A similar process in cerebral arteries results in 
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ischaemic stroke (35). Research in recent decades has increasingly highlighted the roles of oxidative 
stress, inflammation (36-38), macrophage infiltration and deposition of oxidized low-density lipoprotein 
(ox-LDL) cholesterol in the walls of blood vessels and endothelial dysfunction in the pathophysiology of 
atherosclerosis (35, 39). Results from preclinical studies suggest that SIRTs are involved in the regulation 
of many of these pathways. This review focuses on the vascular biology of SIRT1, SIRT3 and SIRT6, 
with a focus on the roles of these enzymes and their modulators on biological molecules and processes 
involved in atherogenesis, including lipid metabolism, inflammation and endothelial function. 
 
3. Potential for SIRTs to modulate factors involved in the development atherosclerosis 
3.1. Lipid modification 
The deposition of oxidized lipids in arterial walls is a characteristic of atherosclerosis (35, 39). 
Pharmacological modification of plasma lipid profiles, in particular the reduction of low-density 
lipoprotein cholesterol (LDL-C), has been shown to be effective in the primary (40) and secondary (41) 
prevention of cardiovascular events. Epidemiological studies have repeatedly demonstrated associations 
between HDL-C and reduced risk of cardiovascular disease, although the causal relationship of this 
relationship has been called into question by careful studies including a large, well-conducted Mendelian 
randomization investigation (42). Lipid-modifying effects of SIRTs have been described, and, therefore 
SIRTs may have the potential to alter the course of atherogenesis (43) (Figure 1).   
SIRT1 modulates cholesterol biosynthesis in the liver (44) resulting in reduction of serum lipid levels(45). 
These effects is associated with the fact that SIRT1 is a positive regulator of the liver X receptor (LXR) 
proteins, important regulators of the metabolism of fatty acids, cholesterol, and glucose. LXR regulates 
reverse cholesterol transport, a process that removes cholesterol from macrophages and prevents foam cell 
formation. SIRT1 may promote deacetylation of LXRs at lysine K432 (44). Deacetylation and subsequent 
activation of LXR increase the expression of ATP-binding cassette (ABC) sub-family A member (ABCA) 
M
AN
US
CR
IP
T
 
AC
CE
PT
ED
ACCEPTED MANUSCRIPT
  
1 and ABC sub-family G member (ABCG) 1, which contribute to the reverse cholesterol transport and the 
suppression of foam cell formation and cholesterol loading in macrophages (44). Moreover, SIRT1 
interacts with transcription factors including peroxisome proliferator-activated receptor gamma (PPARγ), 
nuclear receptor co-repressor (N-CoR) (46), and peroxisome proliferator-activated receptor gamma co-
activator 1-alph (PGC-1a) (47), and may also contribute to activation of LXR in cells via the NF‑κB 
pathways (14). 
Of particular interest is the observation that pharmacological activation of SIRT1 can increase LDLR 
expression in mice through a reduction in secretion of proprotein convertase subtilisin/kexin 9  
(PCSK9) (48), which targets LDL receptors for internalization in hepatic cells and thereby reduces the 
capacity of the liver to take up circulating LDL (49, 50). Monoclonal antibodies directed against PCSK9 
have shown great efficacy in lowering circulating LDL-C concentrations and are very promising agents in 
the prevention of cardiovascular disease (CVD) (49, 50). Also, SIRT6 can reduce LDL-C levels through 
regulation of the PCSK9 gene (34). Deficiency of hepatic SIRT6 increased PCSK9 gene expression and 
LDL-C. SIRT6 can be recruited by forkhead transcription factor FOXO3 to the proximal promoter region 
of the PCSK9 gene and deacetylates histone H3 at lysines 9 and 56, which suppress the gene expression. 
Moreover, overexpression of SIRT6 in mice fed a high-fat diet lowers LDL-C (34). FOXO3 and SIRT6 
also suppress the Srebp2 gene expression, a major regulator of cholesterol biosynthesis in the liver. SIRT6 
and FOXO3, have an impact on total cholesterol levels in the circulation via regulation of the Srebp2 gene 
(51). 
 
3.2. Reduction of oxidative stress 
Anti-atherosclerotic actions of SIRTs may derive from their potential to reduce the severity of oxidative 
stress and stress-induced endothelial injury (52) (53). SIRT1 exerts antioxidant effects by modulating 
FOXO signaling (54). FOXO proteins have many functions, including cell cycle, metabolism, apoptosis, 
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stress resistance, DNA repair, and aging (55). Deacetylation and then activation of FOXO1, 3 and 4 
transcription factors by SIRT1 reduces oxidative stress by induction of anti-oxidative enzymes in 
endothelial cells (56). SIRT1 promotes the expression of FOXO target genes associated with stress 
resistance, and decreases the transcription of genes associated with apoptosis (57). Genetic variations at 
the SIRT1 and FOXO1 loci have been found to be associated with carotid atherosclerosis. A pronounced 
effect was found for two SNPs (rs10507486 and rs2297627) at FOXO1 and common carotid intima-media 
thickness (58). SIRT1 has been shown to promote the ubiquitination and degradation of FOXO3a, which 
protects endothelial progenitor cells against oxidative stress-induced apoptosis (59).  
SIRT3 reduces intracellular activity of reactive oxygen species (ROS) via deacetylation and stimulation of 
mitochondrial superoxide dismutase 2 (SOD2) (19), an enzyme responsible for the conversion of 
superoxide to molecular oxygen or hydrogen peroxide. (53). Correspondingly, it has been demonstrated 
that SIRT3 deficiency in murine and human pulmonary artery smooth muscle cells was associated with 
induction of the transcription factors involved in the pathogenesis of pulmonary artery hypertension 
hypoxia-inducible factor 1A (HIF1A), signal transducer and activator of transcription-3 (STAT3), and 
nuclear factor of activated T cells 2 (NFATc2) (60). Moreover, SIRT3 deficiency induces a mild, 
superoxide-dependent endothelial dysfunction in mice fed a high-cholesterol diet (61). 
 
3.3. Anti-inflammatory actions 
SIRTs have the potential to reduce the inflammatory component of atherosclerotic disease. In particular 
this may occur through regulation of nuclear factor-kB (NF-kB), which regulates the expression of 
cytokines, chemokines and other pro-inflammatory agents (62). 
SIRT6 is an important regulator of inflammation. In endothelial cells, the down regulation of SIRT6 is 
associated with enhanced expression of NF-kB, while overexpression of SIRT6 is associated with 
diminished NF-kB activity. SIRT6 thus appears to modulate the up-regulation of genes involved in 
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inflammation, vascular remodelling, oxidative stress and angiogenesis including interleukin1β (IL-1β)  
(7). 
 In a murine model, haploinsufficiency of SIRT6 results in more rapid atherosclerotic plaque formation 
and greater carotid plaque instability than in homozygous SIRT6 controls. The homozygote animals had 
greater expression of inflammatory cytokines (63). Interestingly, the study also found that expression of 
SIRT6 was lower in carotid arteries from patients with atherosclerotic disease, compared to normal 
controls (63) 
 
3.4. Macrophage migration and foam cell deposition  
Uptake of ox-LDL into endothelial cells, an important stage in the development of atherosclerosis, is 
achieved via several scavenger receptors, for example lectin-like oxidized low-density lipoprotein 
receptor-1 (Lox-1) and CD36 (64). Inhibition of Lox-1 expression would appear to be a potential 
therapeutic strategy against atherosclerosis (65). SIRT1 reduces the expression of the scavenger receptor 
Lox-1 in macrophages (66), and may thereby act to slow the development of foam cells. Reduction of 
Lox-1 expression by SIRT1 is associated with suppression of NF-signaling by deacetylation of RelA/p65 
(66). SIRT1 also exerts CD36 dependent and independent activities related to ox-LDL uptake (57). 
Moreover, it was also indicated that SIRT1 does not affect scavenger receptor class B type I (SR-B1) 
which mediates cellular HDL cholesterol uptake (44). In addition, SIRT1 may stabilize existing 
atherosclerotic plaques by enhancing the activity of tissue inhibitor of metalloproteinase 3 in vascular 
smooth muscle cells (67).  
 
3.5. Autophagy  
Autophagy is catabolic process through which damaged organelles and macromolecules are degraded and 
recycled within the cell. Macrophage autophagy plays a protective role in atherosclerosis by reducing 
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inflammation and promoting cholesterol efflux (68). SIRT1 can regulate autophagy by both epigenetic 
mechanisms through histone modification and by posttranslational mechanisms through the action of 
forkhead transcription factors (FOXO) (69). The primary deacetylation target of SIRT1 is lysine 16 on 
histone H4 (H4K16). H4K16 deacetylation inhibits the transcription of genes involved in the initial and 
late stages of autophagy (70). SIRT1 may directly interact with ATG5, ATG7, and Atg8/LC3 (71). 
Indirectly, SIRT1 might regulate autophagy by deacetylation of FOXO1 and FOXO3, which cause 
increased expression of molecules associated with autophagy. FOXO1 activation stimulates the expression 
of Rab7, which leads to the maturation of autophagosomes (72). Deacylation of FOXO3 increases the 
expression of Bnip3, which is critical for the induction of autophagy (73).  
SIRT6 also protects against atherosclerosis by reducing foam cell formation through an autophagy-
dependent pathway. He et al. indicated that SIRT6 overexpression lowers the level of miR-33, which not 
only increases autophagy flux but also upregulates ABCA1 and ABCG1 expression, promoting 
cholesterol efflux and preventing macrophage foam cell formation at the same time (74). 
 
3.6. Vascular function 
Two recent studies conducted in mouse models have investigated the effects of SIRT6 upon vascular 
function using similar methods (26, 28). Endothelial derived relaxation, provoked by an acetylcholine 
challenge, was impaired in haploinsufficient SIRT6+/- mice (28) and when the function of SIRT6 was 
attenuated by small hairpin RNAs. Haploinsufficiency SIRT6+/- mice had increased rates of atherogenesis 
associated with elevated vascular cell adhesion molecule-1 (VCAM-1), an inflammatory cytokine. 
Correspondingly, SIRT6 overexpression was associated with reduced expression of pro-atherosclerotic 
genes (including tumour necrosis factor (TNF) family members and reduced adhesion of monocytes to 
endothelial cells) (28) 
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4. SIRTs and cigarette smoke 
Cigarette smoke causes generalized endothelial dysfunction (75, 76), which is usually an indicator of an 
increased oxidative stress. In smokers and in subjects with diabetes, SIRT1 expression and/or activity may 
be decreased, despite the fact that the protective effects of SIRT1 against oxidative stress would be 
especially helpful in this situation. It was found that the SIRT1 activator SRT2104 is safe and well 
tolerated in otherwise healthy cigarette smokers and positively effects on lipid profiles through reducing 
LDL-cholesterol concentrations in serum by 11%, but did not indicate beneficial effects on vascular, 
endothelial, or platelet function compared with placebo (77). Resveratrol, probably via a SIRT1-
dependent mechanism, may prevent the adverse vascular effects of cigarette smoking by reducing 
cigarette smoke-induced oxidative stress and preventing pro-inflammatory phenotypic alterations in 
vascular tissues (78). Additionally, it was shown that SIRT1-PARP-1 axis plays a pivotal role in 
regulation of autophagy induced by cigarette smoke (79). 
 
5. SIRTs and statins 
In addition to their well-documented lipid-modifying effects, statins (3-hydroxy-3-methylglutaryl–
coenzyme A reductase inhibitors) have pleiotropic vascular protective effects associated with 
improvement or restoration of endothelial function, enhanced activity of endothelial nitric oxide synthase 
(eNOS), and reduction of oxidative stress (80). eNOS protects the cardiovascular system from 
atherosclerosis by regulating vascular relaxation (81). A positive correlation was found between eNOS 
and SIRT1 expression in subjects receiving statins. Ota et al. indicated that an increase in eNOS activation 
caused by statins could promote SIRT1 (82). Kilic et al. shown that SIRT1 expression is increased and 
eNOS expression is decreased in patients with atherosclerosis and statin, atorvastatin and rosuvastatin, 
therapy may reduce SIRT1 expression and increase eNOS expression, to the similar levels as in healthy 
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population, independent from the studied SIRT1 gene variants (rs7069102C>G and rs2273773C>T) (83). 
Therefore, statin treatment could exert its protective effect on cardiovascular disease through the 
inhibition of SIRT1 expression. Conversely, previous studies, demonstrated an increase in SIRT1 
expression with statin treatment (84, 85).  
 
6. Pharmacological modulators of SIRTs 
SIRTs present an interesting and attractive therapeutic target in the prevention of atherosclerotic 
cardiovascular disease. The wide-ranging anti-atherosclerotic effects of SIRT activation afford an 
opportunity simultaneously to influence multiple components of the development of atherosclerotic 
cardiovascular disease with a single drug target. Furthermore, a number of currently available drugs and 
nutraceuticals have been demonstrated to activate SIRTs directly or via allosteric activation (86, 87). 
Thus, the clinical manipulation of SIRTs may be achievable without the costly and time-consuming 
process of discovering new drug targets. Pharmacological modulators have been best characterized for 
SIRT1 and several of these are discussed below. In order to test the hypotheses that these agents may be 
beneficial in the treatment and prevention of cardiovascular disease, possibly long-term, outcomes-based 
placebo-controlled clinical trials would be necessary. However such studies are likely to be expensive and 
relatively difficult to conduct. The short-term studies, which simultaneously measure expression of SIRTs 
and different parameters of cardiovascular risk in patients taking SIRT modulators, may go some way to 
addressing the question. 
 
6.1. Metformin 
Metformin is a safe and widely used antidiabetic drug. In addition to its well-characterized reductions in 
plasma glucose, it has anti-inflammatory properties with the potential to modulate important components 
of the pathophysiology of atherosclerosis. (88, 89). Metformin increases SIRT1 expression and activity 
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and represses the expression of inflammatory markers such as I1-6 and TNF-alpha in patients with carotid 
artery atherosclerosis (90). Metformin has been shown to promote phosphorylation of 5' adenosine 
monophosphate-activated protein kinase (AMPK), which leads to protection against oxidative injuries 
(91). The signaling pathways of metformin-mediated anti-atherosclerotic effects involve inhibition of the 
nicotinamide adenine dinucleotide phosphate (NADPH) oxidase activity and the ROS formation, which 
impair the LOX-1 up-regulation and AKT/eNOS deactivation. Importantly, these protective mechanisms 
are attenuated when SIRT1 and AMPK are repressed (92). 
 
6.2. Resveratrol 
Resveratrol (3,5,4′-trihydroxy-trans-stilbene) is a polyphenol found in natural products including grapes 
(93). Resveratrol is a strong activator of SIRT1 and it is potentially anti-atherosclerotic (2, 94, 95). 
Disappointingly, a well-conducted and extensive meta-analysis did not find any evidence of resveratrol 
supplementation impacting plasma lipids, or other risk factors (96). 
 
6.3. Genistein 
Genistein (4’,5,7-trihydroxyisoflavone) is an isoflavone which is present mainly in soybeans and red 
clover. It has anti-atherosclerotic activities (97-99).  Genistein increases the activity of endothelial nitric 
oxide synthase (eNOS) and the production of nitric oxide (NO) (100). NO is a vasodilator and reduced 
endothelial NO production is a hallmark of endothelial dysfunction and atherosclerosis. In human 
umbilical vein endothelial cells (HUVECs), genistein has been shown to reverse eNOS uncoupling 
induced by ox-LDL, a process modulated by a SIRT1-dependent pathway (100). This observation 
provides an important potential mechanism for the anti-atherosclerotic actions of genistein and SIRT 
activators in general. 
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6.4. Quercetin 
Quercetin is a flavonoid with anti-oxidative and anti-inflammatory activities. It is present in vegetables, 
fruits, herbs and red wine (101). Like genistein, quercetin suppresses ox-LDL-induced endothelial 
dysfunction by activating SIRT1 (102). 
 
6.5. Berberine 
Berberine is a botanical alkaloid mainly isolated from the Chinese herb Coptis chinensis which has been 
proposed as an anti-atherosclerotic agent (103). In a cell-culture model, berberine has been shown to 
reduce the formation of foam cell formation by activating the AMPK-Sirt1-PPAR-γ pathway and by 
reduction of the uptake of ox-LDL by monocytes (104). 
 
6.6. Curcumin 
Curcumin is a polyphenol extract of Curcuma longa. Curcumin enhances cholesterol efflux from 
macrophages, an important step in reverse cholesterol transport, whereby cholesterol is returned to the 
liver for metabolism. This effect of curcumin may result from an increase of ABCA1 expression through 
activation of AMPK-Sirt1-LXRα signaling in THP-1 macrophage-derived foam cells (105). Such effects 
may reduce the development of atherosclerosis and indeed curcumin has been proposed as an anti-
atherosclerotic agent (106). 
 
6.7. Delphinidin-3-glucoside 
Delphinidin-3-glucoside is a natural anthocyanin which is found in a variety of fruits, vegetables, and 
cereals (107). Several studies have demonstrated potentially beneficial effects of anthocyanins on 
atherosclerosis, but the mechanisms have not been fully elucidated (108). It has been shown that 
M
AN
US
CR
IP
T
 
AC
CE
PT
ED
ACCEPTED MANUSCRIPT
  
delphinidin-3-glucoside protects against ox-LDL-induced injury in HUVECs (108).  This effect may be 
mediated via an adenosine monophosphate-activated protein kinase/Sirt1 signaling pathway (109).  
 
6.8. Ginkgolide B 
Ginkgolide B is an extract of the ginkgo leaf and is a natural inhibitor with potentially protective effects 
on endothelial cells (110) Ginkgolide B can protect against endothelial cell injury by reducing LOX-1 and 
increasing Sirt1 (111) and it has been suggested as a potential agent for the  prevention of atherosclerosis 
(111, 112). 
 
6.9 Evaluation of clinical effects of pharmacological modulators of SIRTs 
The compounds described above have shown promise in varying degrees in the modulation of SIRT 
function. More rigorous evaluation of these compounds is needed before any recommendations can be 
made with respect to their clinical use. Metformin is probably the most promising candidate in this 
respect, because its widespread availability as a pharmaceutical preparation would make a large 
randomised controlled trial realatively easy to facilitate (88-92). Such a trial could be used to measure the 
effect of the drug on SIRT function and clinical outcomes, to determine whether these effects were 
correlated with one another. Natural products such as resveratrol, genistein, quercetin, berberine, 
curcumin, delphinidin-3-glucoside and ginkgolide B may be harder to investigate robustly owing to 
difficulties in measuring dietary intake in observational studies and because of the difficulty in eliminating 
variability between batches of supplements used in controlled studies (94-112). Perhaps the most practical 
approach to further research would be to investigate metformin initially as a ‘proof of concept’ and then to 
investigate natural products if studies with metformin suggested a SIRT-mediated benefit of metformin. 
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7. Conclusions 
SIRTs appear to have a prominent role in vascular biology, and in preclinical models they promote a 
variety of physiological effects, which would be expected to oppose atherogenesis. Preclinical studies 
suggest roles for SIRTs in protecting vascular smooth muscle and endothelial cells from the deleterious 
effects associated with lipid deposition, oxidative stress, and inflammation. Although clinical data are 
currently limited, and caution must be applied when extrapolating from the results of preclinical studies, 
the availability and safety of SIRT activators such as metformin and resveratrol make possible the studies 
that will be necessary to better understand the role of SIRTs in human atherosclerosis. These encouraging 
observations necessitate rigorous large clinical trials to determine the roles of SIRT activators on cardiac 
outcomes such as incident myocardial infarction and mortality.  
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Figure 1: An overview of potential interactions of SIRTS with pathophysiological processes in atherosclerosis. 
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HIGHLIGHTS: 
• The sirtuins, silent mating-type information regulation 2 (SIRTs), are a family of 
nicotinamide adenine dinucleotide (NAD+)-dependent histone deacetylases  
• SIRTS have important roles in regulating energy metabolism and senescence.  
• Activation of SIRTs appears to have beneficial effects on lipid metabolism and 
antioxidants 
• The availability and safety of SIRT activators such as metformin and resveratrol 
provide an excellent opportunity to conduct research to better understand the role of 
SIRTs in human atherosclerosis.  
 
